Perspective Therapeutics (CATX) Consolidated Net Income (2010 - 2026)

Perspective Therapeutics (CATX) has 17 years of Consolidated Net Income data on file, last reported at -$28.9 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income changed N/A year-over-year to -$28.9 million; the trailing twelve-month figure through Mar 2026 stood at -$28.4 million (down 5698.16% YoY), and the FY2025 full-year result was $514000.0, up 154.16% from the prior year.
• Consolidated Net Income eased to -$28.9 million in Q1 2026, from $514000.0 in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $514000.0 in Q2 2025 to a low of -$28.9 million in Q1 2026.
• A 5-year average of -$4.4 million and a median of -$1.5 million in 2023 frame the typical range for Consolidated Net Income.
• Across the five-year window, Consolidated Net Income plunged 1046.13% in 2022 and surged 204.9% in 2025, its largest moves.
• Tracing CATX's Consolidated Net Income over 5 years: stood at -$2.3 million in 2022, then tumbled by 127.82% to -$5.2 million in 2023, then soared by 90.55% to -$490000.0 in 2024, then surged by 204.9% to $514000.0 in 2025, then tumbled by 5727.43% to -$28.9 million in 2026.
• Business Quant data shows CATX's Consolidated Net Income at -$28.9 million in Q1 2026, $514000.0 in Q2 2025, and -$490000.0 in Q2 2024.